title: Use of a long-acting gonadotropin-releasing hormone agonist for treatment of steroid cell tumors of the ovary.
abstract: OBJECTIVE
  To report a complete serologic response in a 50-year-old women who received long-acting gonadotropin-releasing hormone agonist (GnRH-A) therapy for steroid cell tumor of the ovary, not otherwise specified.
  
  
  METHODS
  Case report.
  
  
  METHODS
  University hospital-based reproductive biology unit.
  
  
  METHODS
  A 50-year-old female patient exhibited persistent elevation of T (>2.0 ng/mL) after surgery for steroid cell tumor of the ovary, not otherwise specified, stage IIA for 3 months. This elevation suggested the presence of some residual active tumor.
  
  
  METHODS
  All tumor evaluations, including those for tumor markers, a thorough physical examination, imaging studies, and evaluations of nuclear medicine studies were negative except for elevated serum T levels. The patient was treated with GnRH-a between the fourth month and sixth month postoperatively.
  
  
  METHODS
  Serum levels of T and tumor survey.
  
  
  RESULTS
  The serum T levels returned to normal limits after administration of the first dose of GnRH-a. Follow-up of tumor survey was negative. The patient was alive and free of disease 26 months after treatment with GnRH-a.
  
  
  CONCLUSIONS
  GnRH-a may be an alternative choice as adjuvant therapy for managing a persistent or recurrent hormone-producing steroid cell tumor of the ovary.
authors.affiliation: Department of Obstetrics and Gynecology, Veterans General Hospital-Taipei, Taiwan, Republic of China.
authors.forename: P H
authors.initials: PH
authors.lastname: Wang
authors.forename: H T
authors.initials: HT
authors.lastname: Chao
authors.forename: W L
authors.initials: WL
authors.lastname: Lee
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D017024:Chemotherapy, Adjuvant; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D005260:Female; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D017273:Goserelin / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D013739:Testosterone / Q000097:blood; D014594:Uterine Neoplasms / Q000556:secondary / Q000601:surgery
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone